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ABSTRACT
Objective. To evaluate the influence 
of the main immunological markers on 
the disease phenotype at diagnosis in 
a large international cohort of patients 
with primary Sjögren’s syndrome (SjS).
Methods. The Big Data Sjögren Pro-
ject Consortium is an international, 
multicentre registry created in 2014. 
As a first step, baseline clinical infor-
mation from leading centres on clinical 
research in SjS of the 5 continents was 
collected. The centres shared a harmo-
nised data architecture and conducted 
cooperative online efforts in order to 
refine collected data under the coor-
dination of a big data statistical team. 
Inclusion criteria were the fulfillment 
of the 2002 classification criteria. Im-
munological tests were carried out us-
ing standard commercial assays. 
Results. By January 2018, the partici-
pant centres had included 10,500 valid 
patients from 22 countries. The cohort 
included 9,806 (93%) women and 694 
(7%) men, with a mean age at diagno-
sis of primary SjS of 53 years, mainly 
White (78%) and included from Euro-
pean countries (71%). The frequency of 
positive immunological markers at di-
agnosis was 79.3% for ANA, 73.2% for 
anti-Ro, 48.6% for RF, 45.1% for anti-
La, 13.4% for low C3 levels, 14.5% for 
low C4 levels and 7.3% for cryoglobu-
lins. Positive autoantibodies (ANA, Ro, 
La) correlated with a positive result in 
salivary gland biopsy, while hypocom-
plementaemia and especially cryoglo-
bulinaemia correlated with systemic 
activity (mean ESSDAI score of 17.7 
for cryoglobulins, 11.3 for low C3 and 
9.2 for low C4, in comparison with 3.8 
for negative markers). The immuno-
logical markers with a great number 
of statistically-significant associations 
(p<0.001) in the organ-by-organ ESS-
DAI evaluation were cryoglobulins (9 
domains), low C3 (8 domains), anti-La 
(7 domains) and low C4 (6 domains).
Conclusion. We confirm the strong in-
fluence of immunological markers on 
the phenotype of primary SjS at diag-
nosis in the largest multi-ethnic inter-
national cohort ever analysed, with a 
greater influence for cryoglobulinae-
mic-related markers in comparison 
with Ro/La autoantibodies and ANA. 
Immunological patterns play a central 
role in the phenotypic expression of the 
disease already at the time of diagno-
sis, and may guide physicians to design 
a specific personalised management 
during the follow-up of patients with 
primary SjS.
Introduction
Primary Sjögren’s syndrome (SjS) is 
a systemic autoimmune disease that 
mainly affects middle-aged women 
with a frequency in general population 
ranging between 0.01 and 0.72% (1). 
Etiopathogenically, the disease targets 
the exocrine glands that are infiltrated 
by lymphocytes (focal sialadenitis) (2). 
More than 95% of patients present with 
oral and/or ocular dryness (3), although 
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they may also develop a wide number 
of systemic (extraglandular) manifes-
tations, which may be the first clinical 
manifestation of the disease (4).
Patients with primary SjS produce a 
wide variety of circulating autoanti-
bodies directed to antigens either nu-
clear or cytoplasmic; in some cases, the 
target antigen is present within specific 
tissues. B lymphocyte hyperactivation, 
the most typical immunopathogenic 
peripheral abnormality of primary SS, 
accounts for these autoantibodies (5, 
6). Immunological markers play a cen-
tral role not only in the diagnosis of 
the disease, but also in predicting their 
outcome as prognostic markers (7). 
The key immunological markers are 
anti-Ro antibodies, as the most specific 
SjS-related autoantibody, and cryo-
globulins and hypocomplementaemia, 
as the main prognostic markers (8). 
Among the variety of immunological 
markers, rheumatoid factor (RF) and 
anti-La antibodies are found in nearly 
half the patients with primary SjS, and 
although not included in the recent 
ACR/EULAR set of classification cri-
teria (9), they should clinically be con-
sidered as key immunological markers 
of the disease (10, 11). Previous studies 
in large multicentre national registries 
have analysed the association between 
immunological markers and the clini-
cal disease phenotype (3, 11-13), with 
heterogeneous results, although most 
identified patients carrying anti-Ro/La 
antibodies as the subset with the most 
clinically and immunologically “ac-
tive” phenotype (14).
The objective of this study was to eval-
uate the influence of the main immuno-
logical markers on the disease pheno-
type at diagnosis in a large internation-
al cohort of patients with primary SjS.
Methods
Patients
The Big Data Sjögren Project Consor-
tium is an international, multicentre 
registry established in 2014 to take a 
“high-definition” picture of the main 
features of primary SjS following a 
worldwide data-sharing cooperative 
merging of pre-existing clinical SjS da-
tabases from leading centres on clinical 
research in SjS of the 5 continents (15). 
The centres share a harmonised data 
infrastructure and conduct cooperative 
online efforts in order to refine already 
collected data in each centre. Inclusion 
criteria were the fulfilment of the 2002 
classification criteria (16). Exclusion 
criteria for considering SjS as a pri-
mary disease were chronic HCV/HIV 
infections, previous lymphoprolifera-
tive processes, and associated systemic 
autoimmune diseases. Diagnostic tests 
for SjS (ocular tests, oral tests and sali-
vary gland biopsy) were carried out 
according to the recommendations of 
the European Community Study Group 
(17). The study was approved by the 
Ethics Committee of the Coordinat-
ing Centre (Hospital Clinic, Barcelona, 
Spain, registry HCB/2015/0869).
Definition of variables
Disease diagnosis was defined as the 
time when the attending physician 
confirmed fulfilment of the 2002 cri-
teria. At this time, the main features 
of the disease were retrospectively 
collected and analysed. The follow-
ing clinical variables were selected 
in order to be harmonised and further 
refined: age, gender, ethnicity, country 
of residence, fulfilment of the 2002 
criteria items, antinuclear antibodies, 
rheumatoid factor, C3 and C4 levels, 
cryoglobulins, and organ-by-organ 
ESSDAI scores. By January 2018, 
the participant centres had included 
10,500 valid patients from 22 coun-
tries. Systemic involvement at diag-
nosis was retrospectively classified 
and scored according to the ESSDAI 
(18), which evaluates 12 domains or 
organ systems, and clinESSDAI (19), 
which evaluates the same domains but 
excluding the last (biological domain). 
Each domain is divided into 3-4 lev-
els according to the degree of activity 
and scored as 0 (no activity), 1 (low 
activity), 2 (moderate activity) or 3 
(high activity). Immunological tests 
were carried out using standard com-
mercial assays (>95% of cases), using 
indirect immunofluorescence to detect 
ANA, ELISA to detect Ro/La antibod-
ies, nephelometry for measuring RF 
and complement levels, and serum 
cryoglobulins by standard measure as 
previously described (20). We divided 
the results obtained according to the 
following two immunological subsets: 
patients with autoantibodies (ANA, 
Ro, La) and those presenting with cry-
oglobulin-related markers (RF, com-
plement levels, cryoglobulins).
Statistical analysis
Descriptive data are presented as mean 
and standard deviation (SD) for con-
tinuous variables and numbers and per-
centages (%) for categorical variables. 
The Chi-square test was used to study 
the association between immunologi-
cal markers with gender, diagnostic 
tests for SjS and systemic involvement. 
T-test was used to compare the mean 
age at diagnosis. All significance tests 
were two-tailed. P-values were ad-
justed for multiple comparisons using 
the false discovery rate (FDR) correc-
tion and values of p<0.001 were con-
sidered significant to avoid false posi-
tive significant results. A heatmap was 
constructed to represent the association 
pattern between immunological mark-
ers and disease phenotype. All analy-
ses were conducted using the R V. 3.2.3 
for Windows statistical software pack-
age (https://www.R-project.org/).
Results
The baseline characteristics of the co-
hort are summarised in Table I. The 
cohort included 9,806 (93%) women 
and 694 (7%) men (female: male ratio, 
14:1), with a mean age at diagnosis of 
primary SjS of 53.1 (SD 14.1) years, 
mainly White (78%) and included pre-
dominantly from European countries 
(71%). Dry mouth was reported by 
9,832 (94%) of patients, dry eyes by 
9,684 (92%), abnormal ocular tests 
in 8,167/9,745 (84%), abnormal oral 
tests in 6,373/8,115 (78%) and positive 
salivary gland biopsy in 6,368/7,777 
(82%) patients.
a) Phenotype of patients carrying 
    autoantibodies
ANA+ patients: ANA were tested in 
9,784 patients, and were positive in 
7,749 (79%). ANA-positive patients 
had a lower mean age at diagnosis (52 
vs. 56 yrs), a higher frequency of ab-
normal ocular tests (86% vs. 82%), 
positive biopsy (84% vs. 79%), mean 
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ESSDAI score (6.7 vs. 4.5) and a higher 
frequency of activity in the lymphade-
nopathy (10% vs. 5%), cutaneous (11% 
vs. 4%), haematological (25% vs. 11%) 
and biological (57% vs. 31%) ESSDAI 
domains in comparison with ANA-neg-
ative patients (Table II).
Ro+ patients: Ro autoantibodies were 
tested in 10,417 patients and were 
positive in 7,617 (73%). Ro-positive 
patients had a lower mean age at di-
agnosis (52 vs. 57 yrs), had a lower 
frequency of dry mouth (92% vs. 95%) 
and dry eyes (91% vs. 97%), a lower 
frequency of positive biopsy (74% vs. 
96%), a higher mean ESSDAI score 
(6.7 vs. 4.7) and a higher frequency 
of activity in the constitutional (10% 
vs. 7%), cutaneous (11% vs. 5%), re-
nal (5% vs. 2%), haematological (26% 
vs. 13%) and biological (58% vs. 31%) 
ESSDAI domains in comparison with 
Ro-negative patients (Table II).
La+ patients: La autoantibodies were 
tested in 10,362 patients and were 
positive in 4,662 (45%). La-positive 
patients had a lower mean age at di-
agnosis (51 vs. 54 yrs), had a higher 
frequency of ocular (86% vs. 82%) and 
oral (81% vs. 76%) diagnostic tests, a 
lower frequency of positive biopsy 
(73% vs. 87%), a higher mean ESS-
DAI score (7.2 vs. 4.3) and a higher 
frequency of activity in the constitu-
tional (11% vs. 7%), lymphadenopa-
thy (10% vs. 8%), glandular (24% vs. 
19%), cutaneous (12% vs. 7%), renal 
(6% vs. 3%), muscular (3% vs. 2%), 
haematological (28% vs. 18%) and 
biological (65% vs. 40%) ESSDAI do-
mains in comparison with La-negative 
patients (Table II).
Ro/La combination patterns: The 3 dif-
ferent combination patterns of anti-Ro/
La antibodies (isolated Ro, isolated La 
and combined Ro and La) were asso-
ciated with differentiated phenotypes 
(Table III). Patients with isolated La+ 
had the highest frequency of dry eye 
(p=0.001) and active glandular and 
muscular domains (p<0.001), while 
patients carrying both autoantibodies 
showed the highest frequency of abnor-
mal ocular and oral (p<0.001) diagnos-
tic tests, and the highest frequencies of 
systemic activity in the lymphadenopa-
thy, cutaneous, renal, haematologi-
cal and biological ESSDAI domains 
(p<0.001).
b) Phenotype of patients with 
    cryoglobulin-related markers
RF+ patients: RF was tested in 8,758 
patients and was positive in 4,245 
(48.5%). RF-positive patients had a 
lower mean age at diagnosis (51 vs. 
54 yrs), had a higher frequency of ab-
normal ocular (88% vs. 83%) and oral 
(82% vs. 76%) tests, a higher mean ES-
SDAI score (7.3 vs. 5.6) and a higher 
frequency of activity in the glandu-
lar (26% vs. 19%), articular (44% vs. 
37%), cutaneous (12% vs. 8%), haema-
tological (29% vs. 18%) and biological 
(66% vs. 39%) ESSDAI domains in 
comparison with RF-negative patients 
(Table IV).
Cryoglobulinaemic patients: Cryoglo-
bulins were tested in 4,732 patients, and 
were positive in 342 (7%). Cryoglobuli-
naemic patients had a higher frequency 
of abnormal oral tests (87% vs. 76%), 
a higher mean ESSDAI score (17.7 vs. 
7.2) and a higher frequency of activity 
in the constitutional (25% vs. 11%), 
lymphadenopathy (23% vs. 10%), glan-
dular (39% vs. 28%), cutaneous (38% 
vs. 11%), renal (15% vs. 5%), muscular 
(8% vs. 3%), PNS (24% vs. 7%), CNS 
(6% vs. 2%), haematological (44% vs. 
25%) and biological (91% vs. 50%) ES-
SDAI domains in comparison with non-
cryoglobulinaemic patients (Table IV).
C4 hypocomplementaemic patients: 
C4 values were measured in 8,556 pa-
tients and were low in 1,234 (14%). C4-
hypocomplementaemic patients had a 
lower mean age at diagnosis (51 vs. 53 
yrs), had a lower frequency of positive 
Table I. Baseline characteristics of 10,500 patients with primary Sjögren’s syndrome.
Variable Patients (%)
Gender (female) 9806 (93.4)
Age at diagnosis 53.1 ± 14.1
Dry eye 9684 (92.2)
Dry mouth 9832 (93.6)
Abnormal ocular tests 8167/9745 (83.8)
     Schirmer’s test 6668/8606 (77.5)
     Rose bengal score/other ocular dye score 2916/3996 (73)
Positive minor salivary gland biopsy 6368/7777 (81.9)
Abnormal oral diagnostic tests 6373/8115 (78.5)
     Unstimulated whole salivary flow 4727/6290 (75.2)
     Parotid sialography 1718/2157 (79.6)
     Salivary scintigraphy 1701/2084 (81.6)
Positive anti-Ro/La antibodies 7917/10420 (76)
     Anti-Ro antibodies 7617/10417 (73.1)
     Anti-La antibodies 4662/10362 (45)
ANA-positive 7749/9784 (79.2)
RF-positive 4245/8758 (48.5)
C3 low 1146/8573 (13.4)
C4 low 1234/8556 (14.4)
Positive cryoglobulins 342/4732 (7.2)
Ethnicity  
     White 7862/10100 (78.0)
     Asian 1345/10100 (13.3)
     Hispanic 556/10100 (5.4)
     Black/African-American 144/10100 (1.4)
     Others 193/10100 (1.9)
Number of patients per continent  
     Europe 7413 (70.6)
     America 1445 (13.8)
     Asia 1410 (13.4)
     Africa 65 (0.6)
     Australia 167 (1.6)
Number of countries per continent  
     Europe 12
     America 4
     Asia 4
     Africa 1
     Australia 1
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biopsy (75% vs. 81%), a higher mean 
ESSDAI score (9.2 vs. 6.0) and a higher 
frequency of activity in the constitu-
tional (13% vs. 10%), lymphadenopa-
thy (13% vs. 8%), cutaneous (18% vs. 
9%), renal (7% vs. 4%), PNS (12% vs. 
5%), haematological (37% vs. 21%) and 
biological (85% vs. 47%) ESSDAI do-
mains in comparison with C4-normo-
complementaemic patients (Table IV).
C3 hypocomplementaemic patients: 
C3 values were measured in 8,573 pa-
tients and were low in 1,146 (13%). 
C3-hypocomplementaemic patients 
had a lower mean age at diagnosis (49 
vs. 53 yrs), had a lower frequency of 
dry mouth (89% vs. 94%) and dry eyes 
(89% vs. 92%), a higher mean ESSDAI 
score (11.3 vs. 5.7) and a higher fre-
quency of activity in the constitutional 
(17% vs. 9%), lymphadenopathy (18% 
vs. 8%), cutaneous (22% vs. 8%), pul-
monary (15% vs. 10%), renal (11% vs. 
4%), PNS (14% vs. 5%), CNS (3% vs. 
2%), haematological (43% vs. 21%) 
and biological (86% vs. 48%) ESSDAI 
domains in comparison with C3-normo-
complementaemic patients (Table IV).
Discussion
In the three last internationally-accept-
ed classification criteria for primary SjS 
(9, 16, 17), autoantibodies have always 
been one of the included criteria and 
always the only laboratory criterion. 
However, the number of autoantibodies 
accepted as criteria has been reduced 
progressively. The 1993 European Cri-
teria included 4 antibodies (ANA, RF, 
Ro/SS-A, and/or La/SS-B), the 2002 
Criteria 2 (anti-Ro/SS-A and anti-La/
SS-B) and the 2016 ACR/EULAR, 
only one (Ro/SS-A) (9, 16, 17), in the 
search for a significant improvement 
of sensitivity and especially specific-
ity. However, the figures for sensitivity/
specificity obtained in the three sets of 
criteria are quite similar (0.93/0.94 for 
the 1993 criteria, 0.96/0.94 for the 2002 
criteria, and 0.96/0.95 for the 2016 cri-
teria). In contrast, other immunological 
markers (cryoglobulins, hypocomple-
mentaemia) that are strongly associated 
with disease prognosis and outcomes 
have been never included in the crite-
ria. In this worldwide study, we have 
confirmed the close association of all 
these immunological markers with the 
phenotype of the disease at the time of 
diagnosis in the largest cohort of pri-
mary SjS patients ever studied.
We found ANA in 80% of patients with 
primary SjS, and as much the immuno-
logical marker most frequently detect-
ed. ANA+ patients had a specific phe-
notype (higher frequency of abnormal 
diagnostic tests, higher mean ESSDAI 
and a higher frequency of activity in 
the lymphadenopathy, cutaneous and 
laboratory-related domains) (Table II). 
Some of these features may be related 
to a late diagnosis (enhanced frequency 
of diagnostic and laboratory tests) in 
comparison with patients with nega-
tive ANA, who are often diagnosed 
earlier on the basis of systemic features 
and positive anti-Ro (21) (nearly 10% 
of Ro+ patients may be ANA negative 
(22)). However, the figures for the main 
systemic features are quite similar to 
that found in patients with anti-Ro anti-
bodies, suggesting that a positive ANA 
result does not add specific value to the 
phenotype observed in anti-Ro carriers. 
Probably, the key usefulness of testing 
ANA would be the early suspicion of 
the disease in non-specialised health-
care settings. Since ANA are the most 
frequent autoantibodies in primary 
SjS and their detection is overwhelm-
ingly available in standard healthcare 
settings, a positive result in a patient 
presenting with sicca features could 
help primary care physicians and other 
specialists to suspect an autoimmune 
origin of sicca symptoms and therefore, 
to refer the patient to the autoimmune 
specialist to discard the disease. 
We found anti-Ro antibodies in 73% of 
our patients, a figure very close to that 
found for ANA. This is a logical con-
sequence of the strong weight of these 
autoantibodies in the classification cri-
teria used (2002), as mandatory criteria 
together with salivary biopsy. Various 
studies have correlated the presence 
of anti-Ro with most of the SjS-relat-
Table II. Association of antinuclear antibodies (ANA), anti-Ro and anti-La autoantibodies 
with epidemiological characteristics, glandular involvement, systemic involvement and im-
munological profile in patients with primary Sjögren’s syndrome. 
Each column shows the results of patients with positive marker.
Variable ANA Positive Ro positive  La positive
 (n=7749)  (n=7617)  (n=4662)
Epidemiology      
Gender (female) 7245 (93.5) 7115 (93.4) 4342 (93.1)
Age at diagnosis 52.1 ± 14.4 51.8 ± 14.4 51.4 ± 14.5
Glandular involvement      
Dry eye 7108 (91.7) 6942 (91.1) 4300 (92.2)
Dry mouth 7223 (93.2) 7045 (92.5) 4338 (93.1)
Abnormal ocular tests 6152/7183 (85.6) 5919/7018 (84.3) 3702/4296 (86.2)
Abnormal oral diagnostic tests 4674/5875 (79.6) 4640/5879 (78.9) 2956/3634 (81.3)
Positive minor salivary gland biopsy 4505/5387 (83.6) 3720/5016 (74.2) 2221/3026 (73.4)
Systemic involvement      
Mean ESSDAI 6.7 ± 8.1 6.7 ± 8 7.2 ± 8.7
Mean clinESSDAI 6.8 ± 8.8 6.7 ± 8.7 7.2 ± 9.5
ESSDAI domains (activity >0)      
Constitutional 687/7359 (9.3) 748/7248 (10.3) 490/4404 (11.1)
Lymphadenopathy 725/7359 (9.9) 666/7248 (9.2) 454/4404 (10.3)
Glandular 1665/7359 (22.6) 1622/7248 (22.4) 1081/4404 (24.5)
Articular 2925/7359 (39.7) 2770/7248 (38.2) 1635/4404 (37.1)
Cutaneous 811/7359 (11) 807/7248 (11.1) 552/4404 (12.5)
Pulmonary 772/7359 (10.5) 775/7248 (10.7) 502/4404 (11.4)
Renal 365/7359 (5) 388/7248 (5.4) 278/4404 (6.3)
Muscular 171/7359 (2.3) 180/7248 (2.5) 133/4404 (3)
Peripheral nervous system (PNS) 439/7359 (6) 440/7248 (6.1) 275/4404 (6.2)
Central nervous system (CNS) 149/7359 (2) 128/7248 (1.8) 80/4404 (1.8)
Haematological 1842/7224 (25.5) 1847/7144 (25.9) 1228/4336 (28.3)
Biological 3987/7006 (56.9) 4106/7021 (58.5) 2767/4284 (64.6)
In bold, statistically significant differences (adjusted p values for multiple comparisons with false dis-
covery rate correction <0.001) in comparison with patients with negative marker.
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Table III. Association of the three combinations of anti-Ro/La antibodies (classification without missing values) with epidemiological 
characteristics, glandular involvement, systemic involvement and immunological profile in patients with primary Sjögren’s syndrome.
Variable Isolated Ro (n=3152) Ro and La (n=4412) Isolated La (n=248) Adjusted p
Epidemiology        
Gender (female) 2961 (93.9) 4103 (93) 237 (95.6) 0.126
Age at diagnosis 52.6 ± 14.1 51.3 ± 14.6 52.2 ± 13.7 0.002
Glandular involvement        
Dry eye 2833 (89.9) 4064 (92.1) 236 (95.2) 0.001
Dry mouth 2893 (91.8) 4104 (93) 232 (93.5) 0.126
Abnormal ocular tests 2395/2919 (82) 3497/4055 (86.2) 203/239 (84.9) <0.001
Abnormal oral diagnostic tests 1849/2447 (75.6) 2770/3404 (81.4) 184/228 (80.7) <0.001
Positive minor salivary gland biopsy 1578/2113 (74.7) 2107/2858 (73.7) 113/166 (68.1) 0.179
Systemic involvement        
Mean ESSDAI 5.8 ± 6.7 7.3 ± 8.7 5.9 ± 7 <0.001
Mean clinESSDAI 6 ± 7.4 7.3 ± 9.6 6.2 ± 7.8 <0.001
ESSDAI domains (activity >0)        
Constitutional 275/3034 (9.1) 467/4161 (11.2) 23/242 (9.5) 0.015
Lymphadenopathy 234/3034 (7.7) 429/4161 (10.3) 25/242 (10.3) 0.001
Glandular 633/3034 (20.9) 986/4161 (23.7) 95/242 (39.3) <0.001
Articular 1186/3034 (39.1) 1565/4161 (37.6) 69/242 (28.5) 0.006
Cutaneous 263/3034 (8.7) 541/4161 (13) 11/242 (4.5) <0.001
Pulmonary 304/3034 (10) 469/4161 (11.3) 33/242 (13.6) 0.115
Renal 119/3034 (3.9) 268/4161 (6.4) 10/242 (4.1) <0.001
Muscular 68/3034 (2.2) 112/4161 (2.7) 21/242 (8.7) <0.001
Peripheral nervous system (PNS) 173/3034 (5.7) 265/4161 (6.4) 10/242 (4.1) 0.239
Central nervous system (CNS) 53/3034 (1.7) 75/4161 (1.8) 5/242 (2.1) 0.932
Haematological 650/2998 (21.7) 1188/4093 (29) 39/242 (16.1) <0.001
Biological 1430/2927 (48.9) 2659/4043 (65.8) 107/240 (44.6) <0.001
In bold, statistically significant associations (adjusted p values for multiple comparisons with false discovery rate correction <0.001).
Table IV. Association of rheumatoid factor (RF), low C3 levels, low C4 levels and cryoglobulins (Cryog) with epidemiological  characte-
ristics, glandular involvement, systemic involvement and immunological profile in patients with primary Sjögren’s syndrome. Each column 
shows the results of patients with positive marker.
Variable RF positive (n=4245) Cryog positive (n=342) Low C4 levels (n=1234) Low C3 levels (n=1146)
Epidemiology        
Gender (female) 3942 (92.9) 312 (91.2) 1156 (93.7) 1077 (94)
Age at diagnosis 50.8 ± 14.6 53.5 ± 14.2 51.3 ± 14.7 48.9 ± 14.2
Glandular involvement        
Dry eye 3890 (91.6) 320 (93.6) 1125 (91.2) 1019 (88.9)
Dry mouth 3958 (93.2) 321 (93.9) 1138 (92.2) 1018 (88.8)
Abnormal ocular tests 3471/3920 (88.5) 300/326 (92) 1006/1174 (85.7) 944/1090 (86.6)
Abnormal oral diagnostic tests 2668/3238 (82.4) 244/279 (87.5) 772/972 (79.4) 763/930 (82)
Positive minor salivary gland biopsy 2538/2921 (86.9) 209/241 (86.7) 658/875 (75.2) 606/747 (81.1)
Systemic involvement        
Mean ESSDAI 7.3 ± 8.3 17.7 ± 17.4 9.2 ± 10.9 11.3 ± 12.5
Mean clinESSDAI 7.3 ± 9.1 17.7 ± 19.1 9.1 ± 11.9 11.4 ± 13.7
ESSDAI domains (activity >0)        
Constitutional 396/3972 (10) 81/321 (25.2) 162/1202 (13.5) 192/1104 (17.4)
Lymphadenopathy 417/3972 (10.5) 74/321 (23.1) 157/1202 (13.1) 197/1104 (17.8)
Glandular 1033/3972 (26) 125/321 (38.9) 311/1202 (25.9) 302/1104 (27.4)
Articular 1739/3972 (43.8) 160/321 (49.8) 486/1202 (40.4) 480/1104 (43.5)
Cutaneous 474/3972 (11.9) 122/321 (38) 220/1202 (18.3) 247/1104 (22.4)
Pulmonary 469/3972 (11.8) 61/321 (19) 153/1202 (12.7) 166/1104 (15)
Renal 188/3972 (4.7) 47/321 (14.6) 84/1202 (7) 124/1104 (11.2)
Muscular 89/3972 (2.2) 25/321 (7.8) 28/1202 (2.3) 45/1104 (4.1)
Peripheral nervous system (PNS) 239/3972 (6) 76/321 (23.7) 145/1202 (12.1) 156/1104 (14.1)
Central nervous system (CNS) 63/3972 (1.6) 18/321 (5.6) 26/1202 (2.2) 38/1104 (3.4)
Haematological 1122/3888 (28.9) 140/321 (43.6) 447/1198 (37.3) 471/1103 (42.7)
Biological 2519/3817 (66) 291/321 (90.7) 1015/1193 (85.1) 935/1086 (86.1)
In bold, statistically significant differences (adjusted p values for multiple comparisons with false discovery rate correction <0.001) in comparison with 
patients with negative marker.
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ed features, including parotidomegaly, 
lymphadenopathy, cutaneous vasculi-
tis, neurologic disease and serologic 
hallmarks such as the presence of hy-
pergammaglobulinaemia, rheumatoid 
factor and cryoglobulins (10). Our re-
sults confirm a specific phenotype con-
sisting of patients diagnosed at younger 
age, with a lower frequency of sicca 
syndrome and positive salivary gland 
biopsy, and a higher frequency of activ-
ity in the constitutional, cutaneous and 
laboratory ESSDAI domains. A recent 
study by Quartuccio et al. compared 
Ro/La+ and Ro/La- patients (23) and 
found a younger age at diagnosis and 
a higher frequency of glandular swell-
ing, purpura, leukopenia, lymphoma, 
low C3, low C4, hypergammaglobuli-
naemia, rheumatoid factor and serum 
cryoglobulins in Ro/La+ patients, while 
we have recently reported that anti-Ro/
SS-A and anti-La/SS-B antibodies were 
also associated with global systemic ac-
tivity, especially anti-Ro/SS-A, whose 
positivity at diagnosis also correlated 
with a higher activity score in the ar-
ticular, cutaneous and renal domains in 
a Spanish multicentre study (3).
Anti-La antibodies were detected in 
45% of our patients and overwhelm-
ingly associated with the presence of 
anti-Ro antibodies (95% of cases). 
Probably for this reason, the pheno-
type of La carriers was very similar to 
that reported for Ro carriers. However, 
when we analysed the phenotype of Ro/
La patients according to the different 
antibody combinations, we found that 
the most striking phenotypic differ-
ences were found in patients carrying 
the two antibodies in comparison with 
those who carried only a single anti-
body, with a higher frequency of abnor-
mal diagnostic tests, the highest mean 
ESSDAI score among the three groups, 
and the highest frequency of systemic 
activity in nearly all the ESSDAI do-
mains (especially in the constitutional, 
lymphadenopathy, cutaneous, renal and 
haematological domains) (Table III). In 
a previous study, Locht et al. (24) re-
ported a higher frequency of internal 
organ involvement in patients carry-
ing anti-La and anti-Ro in comparison 
with those carrying anti-Ro alone, and 
other studies also reported similar re-
sults (25, 26). In contrast, recent stud-
ies have reported a lower frequency of 
abnormal diagnostics tests (Schirmer 
test, UWSF and salivary gland biopsy) 
in isolated La carriers (27, 28). The 
influence of Ro/La on the phenotypic 
expression of primary SjS at diagnosis 
could be driven by immunogenetic dif-
ferences. The presence of these autoan-
tibodies has been significantly linked 
with specific HLA-D epitopes (B1*03 
and QB1*02, an association even more 
prominent and extended to QA1*0501 
when patients were stratified according 
to the presence of La/SSB autoantibod-
ies (29), suggesting a similar (but not 
identical) genetic susceptibility for Ro 
and La carriers.
Rheumatoid factor was detected in 
nearly half our patients, who also 
showed a specific phenotype consisting 
of a young age at diagnosis, a higher 
frequency of abnormal diagnostic tests, 
a high mean ESSDAI score, and a 
high frequency of systemic activity in 
the glandular, articular, cutaneous and 
haematological domains (Fig. 1). Pre-
vious studies reported that RF has an 
independent association with the main 
clinical and immunological features of 
the disease (10), and we found recently 
that RF was associated with a higher 
ESSDAI score both at diagnosis and 
at the end of follow-up (30). Thus, RF 
detection in primary SjS is clinically 
useful, especially for the diagnosis of 
some subsets of patients with primary 
SS, such as those with extraglandular 
manifestations or with circulating cryo-
globulins.
Cryoglobulinaemia had no influence 
on the glandular disease expression 
for both subjective and objective glan-
dular features (except for an increased 
frequency of abnormal oral diagnostic 
tests), but play a key role in driving a 
multi-systemic phenotype with statisti-
cally-significant higher frequencies in 
all ESSDAI domains but two (articular 
and pulmonary) (Fig. 1). In fact, pa-
Fig. 1. Heat map of the main statistically-significant associations (adjusted p values <0.001) between 
immunological markers and disease phenotype.
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tients with cryoglobulinaemia showed 
the highest mean ESSDAI among all 
the immunological subsets, being 4-fold 
higher than the mean score found in pa-
tients with no immunological markers 
and 3-fold higher than that found in 
ANA+ or Ro+ patients (Fig. 2). This is 
closely related to the presence of a sys-
temic vasculitic process, since although 
many patients with cryoglobulinaemia 
remain asymptomatic, the percentage 
of patients with circulating cryoglobu-
lins who develop vasculitic symptoms 
in primary SjS is 35% (20). The pres-
ence of cryoglobulinaemic vasculitis at 
the diagnosis of primary SS is indepen-
dently associated with mortality, and is 
closely linked with a higher baseline 
ESSDAI score (31). 
In previous studies in multicentre na-
tional cohorts, we found a significant 
association between low complement 
levels and the main systemic SS fea-
tures, including both extraglandular 
disease (fever, articular involvement, 
cutaneous vasculitis, and peripheral 
neuropathy) and immunological mark-
ers (cryoglobulinaemia, rheumatoid 
factor) (7, 32), and recently Shiboski et 
al. (33) have reported that sicca patients 
with hypocomplementaemia were 6 
times more likely to progress to definite 
SjS. In addition, hypocomplementae-
mia is also closely associated with the 
two main adverse outcomes of primary 
SS (lymphoma development and death) 
(34), although two studies (7, 35) re-
ported a predominant role for low C4. 
This study is the first to analyse sepa-
rately the phenotype associated with 
either low C4 or low C3 values, and we 
found significant differences. Patients 
with C4-hypocomplementaemia were 
older and had an enhanced frequency 
of positive salivary gland biopsy, while 
those with C3-hypocomplementaemia 
were younger and had a lower frequen-
cy of sicca symptoms. Both subsets of 
patients showed higher mean ESSDAI 
scores (Fig. 2) and a close association 
with systemic activity in the ESSDAI 
domains, although systemic activity 
was more pronounced in C3-hypocom-
plementaemic patients (Fig. 1). This is 
a new finding, in contrast with previous 
studies carried out in more geograph-
ically-homogeneous populations that 
showed a predominant role for low C4 
levels. Probably, the different degree of 
association between hypocomplemen-
taemia and cryoglobulinaemia (cryo-
globulinaemia is more frequently asso-
ciated with consumption of C4 factor) 
could explain these differences with 
previous studies, since the frequency 
of cryoglobulinaemia is strongly influ-
enced by geographical and ethnicity de-
terminants (15).
The results of this study, however, 
should be interpreted with caution, and 
some limitations should be pointed 
out. Studies including clinical big data 
may detect some differences which, al-
though statistically significant, may not 
be clinically relevant, and further stud-
ies are necessary to confirm their clini-
cal relevance in smaller, but more ho-
mogeneous, populations. This was the 
reason why we considered statistically-
significant p-values less than 0.001 af-
ter adjusting for multiple comparisons 
using the false discovery rate. The pre-
dominant presence of European patients 
could also limit the generalisation of the 
results in other ethnic subpopulations 
Fig. 2. Mean ESS-
DAI score (2a) and 
clinESSDAI score 
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less frequently reported. Other sources 
of heterogeneity may include the vari-
able amount of missing data for some 
variables and the immunological assays 
used by the different centres, although 
all are commercial tests and more than 
80% used the same technique (ELISA) 
to test for Ro/La autoantibodies and 
ANA were overwhelmingly tested for 
by indirect immunofluorescence.
In summary, we confirm a strong influ-
ence of immunological markers on the 
phenotype of primary SjS at diagnosis 
in the largest multi-ethnic international 
cohort ever analysed, with a greater in-
fluence for cryoglobulinaemic-related 
markers in comparison with Ro/La au-
toantibodies and ANA. Immunological 
patterns play a central role in the pheno-
typic expression of the disease already 
at the time of diagnosis, and may guide 
physicians to design a specific person-
alised management during the follow-
up of patients with primary SjS.
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